Comprehensive Analysis of Effectiveness and Cost‐Effectiveness of Treatments for Psoriasis Integrating Clinician‐ and Patient‐Reported Outcomes: A Cohort Study From SPEECH
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Abstract
Effective and cost‐effective management strategies for psoriasis are crucial for clinical decision‐making. In the management of psoriasis, evidence concerning the effectiveness and cost‐effectiveness of therapies from both clinicians’ and patients’ perspectives is vital for clinical decision‐making. To compare the effectiveness and cost‐effectiveness of acitretin, methotrexate, phototherapy, and biologics (adalimumab, ustekinumab, guselkumab, secukinumab, and ixekizumab) in treating chronic plaque psoriasis, we collected the data from the Shanghai Psoriasis Effectiveness Evaluation CoHort (SPEECH), an observational, multicenter, and prospective registry. Integrating both clinician‐ and patient‐reported outcomes allows for a comprehensive evaluation of treatment impacts, capturing clinical disease improvements as well as patient‐perceived quality of life enhancements, thereby providing a more complete perspective compared to analyses focusing solely on clinical outcomes. Proportions of patients achieving 75% improvement in Psoriasis Area and Severity Index (PASI 75), PASI 90, PASI 100, minimally important difference in Dermatology Life Quality Index (DLQI MID), DLQI 0/1, and Patient Global Assessment (PtGA) MID at 12 weeks were evaluated. The number needed to treat (NNT) and incremental cost per responder (ICPR) were computed for treatments relative to acitretin. A total of 1916 patients with chronic plaque psoriasis were analyzed, with 240 patients on acitretin, 459 on methotrexate, 391 on phototherapy, 64 on adalimumab, 164 on ustekinumab, 97 on guselkumab, 298 on secukinumab, and 203 on ixekizumab. At 12 weeks, patients on methotrexate (adjusted relative risk [RR], 2.03 [95% CI, 1.66–2.48]), phototherapy (RR, 2.01 [95% CI, 1.64–2.46]), adalimumab (RR, 2.22 [95% CI, 1.66–2.96]), ustekinumab (RR, 2.86 [95% CI, 2.27–3.62]), guselkumab (RR, 3.34 [95% CI, 2.54–4.38]), secukinumab (RR, 3.38 [95% CI, 2.74–4.16]), and ixekizumab (RR, 3.59 [95% CI, 2.88–4.47]) were more likely to achieve PASI 75 versus patients on acitretin. Comparable rankings were observed for PASI 90, PASI 100, DLQI MID, DLQI 0/1, and PtGA MID. Additionally, methotrexate and phototherapy demonstrated numerically lower ICPR values compared to other evaluated treatments, while ixekizumab exhibited the lowest ICPR among the biologics. Overall, our study indicated that ixekizumab, secukinumab, guselkumab, and ustekinumab demonstrated superior effectiveness compared to other therapies at 12 weeks. Methotrexate and phototherapy offered the best cost‐effectiveness, while ixekizumab led in cost‐effectiveness among biologics.Keywords
Funding Information
- Shanghai Municipal Hospital Development Center (SHDC2020CR1014B)
- National Natural Science Foundation of China (82273515)
- National Natural Science Foundation of China (82273510)
- Shanghai Municipal Education Commission (2019-01-07-00-07-E00046)
- Program of Shanghai Academic Research Leader (20XD1403300)
This publication has 30 references indexed in Scilit:
- Methods Used for Indirect Comparisons of Systemic Treatments for Psoriasis. A Systematic ReviewSkin Health and Disease, 2022
- Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysisDermatology and Therapy, 2021
- Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysisJournal of the American Academy of Dermatology, 2020
- Comparison of Biologics and Oral Treatments for Plaque PsoriasisJAMA Dermatology, 2020
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologicsJournal of the American Academy of Dermatology, 2019
- Identifying a Core Domain Set to Assess Psoriasis in Clinical TrialsJAMA Dermatology, 2018
- Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasisJournal of the American Academy of Dermatology, 2016
- Ixekizumab for the Treatment of Psoriasis: A Review of Phase III TrialsDermatology and Therapy, 2016
- Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasisJournal of the American Academy of Dermatology, 2015
- Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment periodJournal of the American Academy of Dermatology, 2008